{
    "nctId": "NCT06536881",
    "briefTitle": "Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming",
    "officialTitle": "Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming (GAMMER) Study in Early Stage Breast Cancer Receiving Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Early-stage Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Proportion of participants with self-reported adherence to the fasting regimen",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with histologically-confirmed stage I-III invasive carcinoma of the breast\n* Planning for standard neoadjuvant or adjuvant chemotherapy ddAC or TC for 4 cycles (concurrent anti-HER2 therapy is permitted)\n* Provider physical exam within 4 weeks of consent\n* Eastern Cooperative Oncology Group (ECOG) 0-1 (as per recent provider note or direct confirmation with provider)\n* BMI \u2265 19.5 kg/m2 (as per most recent visit documented in medical record)\n* Willingness to change diet, and provide fecal sample 3 times during study\n\nExclusion Criteria:\n\n* BMI \\<19.5 kg/m2\n* Diabetes\n* History of eating disorder\n* Serious/uncontrolled medical condition (e.g. end stage renal disease on dialysis, cirrhosis, uncontrolled hypertension, seizure disorder, history of bariatric surgery)\n* Pregnant or nursing\n* Use of medications that must be taken with food: allopurinol, aspirin, amiodarone, baclofen, bromocriptine, carvedilol, carbamezpine, cimetidine, diclofenac, doxycycline, fenofibrate, fludrocortisone, glyburide, hydrocortisone, iron supplements, ketorolac, lithium, methylprednisolone, naproxen, niacin, potassium salts, prednisone, procainamide, sevelamer, sulfasalazine, trazodone, valproic acid",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}